According to a new market research study titled Human Microbiome Market to 2025 Global Analysis and Forecasts by Product, Disease and Application. The global human microbiome market is expected to reach US$ 1,197.08 Mn in 2025 from US$ 257.30 Mn in 2017. The market is estimated to grow with a CAGR of 21.8% from 2018-2025. The market is expected to grow due to growing technological advancements in metagenomics and next-generation sequencing, however, the strict government guidelines is hindering the market.
In recent years, for drug discovery the microbiota plays an important role in the efficacy of therapeutic compounds. There is a new phenomenon in the globe. It is the human gut microbiome and the role it may play in the future of human health. Recently various reports have indicated that the human gut microbiome may be implicated in health conditions such as obesity, metabolism, diabetes, immunity and autism. The microbiome has effects on the human physiological functions in various method, such as contributing to metabolic functions, protecting against pathogens, and interacting with immune system development. With regards to the gut microbiome, it had a lot to do with the ubiquitous nature of the source of the microbes and the ability of anyone to acquire it and use it in research.
The disease segment of the human microbiome market is broadly segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders and other diseases. In 2017, obesity segment held the largest share of the market, by disease. However, the diabetes segment is expected to grow at the fastest rate during the coming years owing to the increasing number of diabetes cases in the recent years.
The major players operating in the human microbiome market include Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, and BiomX Ltd. For instance, in April 2016, ENTEROME signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. to research, develop and commercialize novel small molecule FimH antagonists for use in the treatment of inflammatory bowel diseases (IBD). The developments performed by the companies are helping the market to grow in the coming years.
The report segments the global human microbiome market as follows:
Global Human Microbiome Market By Product Probiotics Foods Prebiotics Medical Foods Diagnostic Device Drugs Supplements
Global Human Microbiome Market By Disease Obesity Diabetes Autoimmune Disorders Cancer Mental Disorders Others
Global Human Microbiome Market By Application Therapeutics Diagnostics
Global Human Microbiome Market By Geography
North America U.S. Canada Mexico
Europe U.K. Germany France
Asia Pacific (APAC) Japan China India
Middle East & Africa (MEA) South Africa UAE Saudi Arabia
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
